📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Triveni Engineering Shareholders Approve Composite Scheme of Arrangement with 98.37% Majority
Shareholders and creditors of Triveni Engineering & Industries Limited (TEIL) have overwhelmingly approved a Composite Scheme of Arrangement involving Sir Shadi Lal Enterprises and Triveni Power Transmission. In an NCLT-convened meeting held on December 7, 2025, the resolution received 98.37% support from total votes polled. While the promoter group was 100% in favor, public institutional support stood at 88.33%. This approval is a significant milestone in the company's restructuring and consolidation process.
Key Highlights
98.37% of total equity shareholder votes (15.61 crore votes) were cast in favor of the Composite Scheme of Arrangement.
Promoter and Promoter Group cast 13.34 crore votes with 100% approval for the resolution.
Public institutional investors showed 88.33% support, while public non-institutional investors showed 99.98% support.
Secured and Unsecured creditors also approved the scheme with the requisite majority in separate meetings.
The scheme involves the arrangement between TEIL, Sir Shadi Lal Enterprises Limited, and Triveni Power Transmission Limited.
💼 Action for Investors
The strong shareholder and creditor mandate is a positive signal for the company's restructuring plans; investors should now monitor the final NCLT Allahabad Bench approval for the effective date of the merger.
Nippo Battery: NCLT Chennai hearing update on Amalgamation Scheme
Indo-National Limited (NIPPOBATRY) provided an update on the hearing conducted by the National Company Law Tribunal (NCLT), Chennai Bench, on December 3, 2025, regarding the Scheme of Amalgamation of Helios Strategic Systems Limited with Indo National Limited. The NCLT noted the filing of statutory authorities' reports. The NCLT has listed the petition for further hearing on December 10, 2025. The daily order was available on the NCLT website on December 5, 2025.
Key Highlights
NCLT Chennai heard the matter on December 03, 2025
Further hearing scheduled on December 10, 2025
Daily order available on NCLT website on December 05, 2025
💼 Action for Investors
Investors should monitor further announcements regarding the NCLT hearing outcome on December 10, 2025, and assess the potential impact of the amalgamation on Indo-National Limited.
Race Eco Chain Board to Consider Scheme of Arrangement on Dec 15; Trading Window Closed
Race Eco Chain Limited has scheduled a Board Meeting for December 15, 2025, to consider and approve a Scheme of Arrangement under SEBI regulations. In compliance with insider trading norms, the trading window for the company's securities will be closed from December 9, 2025, until December 17, 2025. This indicates a significant corporate restructuring or reorganization is under discussion. Investors should await the specific details of the scheme to assess its impact on shareholder value.
Key Highlights
Board Meeting scheduled for December 15, 2025, to approve a Scheme of Arrangement.
Trading window for designated persons closed from December 9, 2025, to December 17, 2025.
The proposal is being considered under Regulation 37 of SEBI (LODR) Regulations, 2015.
The meeting will be held at the company's Noida corporate office.
💼 Action for Investors
Investors should wait for the post-meeting disclosure on December 15 to understand the nature of the restructuring before making any investment decisions. The stock may see increased volatility due to the upcoming corporate action.
ICICI Bank to purchase 2% stake in ICICI AMC for ₹21.40 billion
ICICI Bank will acquire an additional 2% shareholding in ICICI Prudential Asset Management Company Limited (ICICI AMC) from Prudential Corporation Holdings Limited (PCHL) for ₹21.40 billion. This acquisition is a related party transaction done at arm's length. The purpose is to maintain the Bank's majority shareholding in ICICI AMC, especially in light of potential stock-based compensation plans. ICICI AMC's turnover for H1-2026 was ₹29.49 billion, with a PAT of ₹16.18 billion.
Key Highlights
ICICI Bank to purchase 2% shareholding in ICICI AMC.
The consideration for the 2% stake is ₹21.40 billion.
ICICI AMC's turnover for H1-2026 was ₹29.49 billion.
ICICI AMC's PAT for H1-2026 was ₹16.18 billion.
ICICI AMC had total assets of ₹48.27 billion at September 30, 2025.
💼 Action for Investors
Investors should monitor the completion of this acquisition and its impact on ICICI Bank's overall stake in ICICI AMC. Keep an eye on ICICI AMC's performance and contribution to ICICI Bank's financials.
Creative Eye Appoints 3 New Independent Directors and Reconstitutes Board Committees
Creative Eye Limited has announced a significant reshuffle of its Board of Directors following a meeting on December 8, 2025. The company accepted the resignation of Ms. Sarita Soni and appointed three new Independent Directors—Dr. Madan Bhalchandra Gosavi, Mr. Charuhas Patil, and Mr. Amit Doshi—for a three-year term. Notably, Dr. Gosavi, a former District Judge and NCLT member, will now chair the Audit and Nomination & Remuneration Committees. The board also adjourned discussions on certain undisclosed agenda items, citing the need for further information.
Key Highlights
Appointment of 3 new Independent Directors for a 3-year term effective December 8, 2025.
Resignation of Ms. Sarita Soni as Independent Director due to pre-occupation.
Dr. Madan Bhalchandra Gosavi, a former NCLT Judicial Member, appointed as Chairman of Audit and NRC Committees.
Full reconstitution of Audit, Nomination & Remuneration, and Stakeholders Relationship Committees.
Adjournment of specific agenda items to a future meeting date pending further clarifications.
💼 Action for Investors
Investors should monitor the company for the announcement of the adjourned meeting date, as pending agenda items may contain strategic updates. The addition of a former NCLT member suggests a focus on strengthening legal and corporate governance.
BHARATIDIL Board Meeting Outcome: Unaudited Financial Results Approved
Bharati Defence and Infrastructure Limited's board approved the unaudited financial results for the quarter ended September 30, 2025. The company's total income for the quarter stood at ₹525.75 lakhs compared to ₹1,072.62 lakhs in the corresponding quarter of the previous year. Net profit for the period was ₹495.25 lakhs. The company's capital restructuring is still in progress. Investors should note the negative reserves of ₹8,03,100.13 lakhs.
Key Highlights
Total Income for Q2 2025: ₹525.75 lakhs
Net Profit for Q2 2025: ₹495.25 lakhs
Paid-up equity share capital: ₹5,029.89 lakhs
Reserves excluding revaluation reserve: ₹(8,03,100.13) lakhs
Basic earnings per share: ₹0.10
💼 Action for Investors
Investors should closely monitor the company's performance, particularly its ability to improve its reserves and manage its capital restructuring. Further analysis of the complete financial statements is recommended.
Welspun Corp associate wins ₹1,165 Crore KSA order
Welspun Corp's associate company, East Pipes Integrated Company (EPIC) in Saudi Arabia, has secured a contract with Saudi Water Authority for manufacturing and supplying steel pipes. The contract is valued at over 485 million SAR, equivalent to approximately ₹1,165 Crore including VAT. The contract duration is six months, and its financial impact will be reflected in Q4FY26 and Q1FY27. This order strengthens EPIC's position as a leading HSAW pipe manufacturer in KSA.
Key Highlights
Order value exceeds 485 million SAR
Order value is approximately ₹1,165 Crore
Contract duration is six months
Financial impact in Q4FY2025-26 and Q1FY26-27
💼 Action for Investors
This order win is a positive development for Welspun Corp. Investors should monitor the company's performance in the coming quarters to see the impact of this order on its financials.
Eros Media Board Meeting on Dec 12 to Approve Q2 and H1 FY26 Results
Eros International Media Limited has scheduled a board meeting for December 12, 2025, to approve un-audited financial results for the quarter and half-year ended September 30, 2025. The company disclosed that its trading window has been closed since April 1, 2024, which is an unusually long period for restricted insider trading. This meeting is a critical step in providing updated financial transparency to the market. Investors will be looking for both standalone and consolidated performance metrics to assess the company's current health.
Key Highlights
Board meeting scheduled for December 12, 2025, to approve financial results.
Results cover the quarter and half-year period ended September 30, 2025.
Trading window for insiders has been closed since April 1, 2024.
Trading window to remain closed until 48 hours after the results are officially announced.
💼 Action for Investors
Investors should wait for the financial results on December 12 to evaluate the company's fundamentals and understand the reasons behind the prolonged trading window closure.
U. Y. Fincorp Q2 Net Profit Jumps 133% YoY to ₹8.09 Cr; Plans ₹50 Cr QIP
U. Y. Fincorp reported a robust net profit of ₹809.32 Lakhs for Q2 FY26, a significant increase from ₹346.57 Lakhs in the previous year's corresponding quarter. While total revenue from operations for the half-year ended September 2025 declined to ₹4,008.94 Lakhs from ₹8,086.83 Lakhs YoY, the bottom line showed strong growth. The company is actively expanding into small-ticket loans through its new brand 'FUNDOBABA' in partnership with Fintech Cloud Private Limited. Furthermore, it has received in-principle approval for a ₹50 Crore fundraise via Qualified Institutional Placement (QIP).
Key Highlights
Net Profit for Q2 FY26 surged 133% YoY to ₹809.32 Lakhs from ₹346.57 Lakhs.
Half-yearly (H1 FY26) net profit rose to ₹1,406.07 Lakhs compared to ₹855.03 Lakhs in H1 FY25.
Earnings Per Share (EPS) for the quarter improved to ₹0.43 from ₹0.18 YoY.
Received in-principle approval from BSE and NSE for a ₹50 Crore private placement through QIP.
Launched 'FUNDOBABA' brand for small-ticket personal and business loans via a joint venture with Fintech Cloud Private Limited.
💼 Action for Investors
Investors should track the progress of the 'FUNDOBABA' fintech expansion and the successful completion of the ₹50 Crore QIP as key growth drivers. While profitability has improved, the decline in operating revenue warrants a closer look at the sustainability of core income streams.
Gallantt Ispat Promoters to Transfer 21.23% Stake via Inter-se Gift for Asset Streamlining
Promoter Chandra Prakash Agrawal and other family members have notified a proposed inter-se transfer of 5,12,13,544 equity shares, representing 21.226% of the company's total share capital. The transaction is an off-market transfer by way of a gift among the promoter group members and HUFs, meaning no cash consideration is involved. This move is intended to streamline family assets and will not change the overall promoter group holding, which remains at 68.931%. The transfer is scheduled to take place on or after December 12, 2025.
Key Highlights
Proposed transfer of 5,12,13,544 equity shares, accounting for 21.226% of the total share capital.
Transaction is an inter-se transfer among promoters via gift deeds with nil consideration.
Total promoter and promoter group holding remains constant at 68.931% post-transaction.
Acquisition is exempt from open offer requirements under SEBI (SAST) Regulation 10(1)(a).
The transfer is expected to occur on or after December 12, 2025.
💼 Action for Investors
This is a routine internal restructuring of promoter holdings for estate planning and does not impact the company's fundamentals. Investors should view this as neutral and continue to focus on the company's operational performance.
Dr. Lal PathLabs Increases Authorized Share Capital to INR 200 Crore
Dr. Lal PathLabs has received shareholder approval via postal ballot to significantly increase its authorized share capital. The limit has been raised from INR 107.96 crore to INR 200 crore, effectively doubling the company's capacity to issue new equity. This change involves a formal amendment to Clause V of the Memorandum of Association. While this is a regulatory enabling provision, it often serves as a precursor to future corporate actions such as bonus issues, rights issues, or equity-based fundraising.
Key Highlights
Authorized share capital increased from INR 107.96 crore to INR 200 crore.
Shareholder approval was obtained through a postal ballot concluded on December 07, 2025.
The new capital structure consists of 20,00,00,000 equity shares with a face value of INR 10 each.
Amendment to Clause V of the Memorandum of Association (MOA) has been officially implemented.
💼 Action for Investors
Investors should monitor the company for upcoming announcements regarding bonus issues or capital raises, as this move creates the necessary legal headroom for such actions.
Dr. Lal PathLabs Shareholders Approve Bonus Issue and New 2025 Employee Stock Unit Plan
Dr. Lal PathLabs has announced the successful passage of seven resolutions via postal ballot, most notably the issuance of bonus equity shares and an increase in authorized share capital. The 'Employee Restricted Stock Unit Plan 2025' was approved with 79.81% favor, although it faced significant institutional dissent with 51.5% of institutional votes cast against it. Additionally, shareholders cleared the path for secondary share acquisitions through a trust and a reduction in the 2022 options reserve. These approvals facilitate the company's capital restructuring and long-term incentive programs.
Key Highlights
Bonus Equity Shares issuance approved with 98.04% of total votes in favor.
Increase in Authorized Share Capital passed with a near-unanimous 99.84% majority.
New 'Employee Restricted Stock Unit Plan 2025' secured 79.81% support despite 51.5% institutional pushback.
Secondary acquisition of shares through a Trust route for ESOP implementation approved by 83.76% of voters.
Reduction of Options Reserve under the 2022 ESOP plan approved with 86.80% majority.
💼 Action for Investors
Investors should view the bonus issue as a positive move for share liquidity, though the high institutional dissent on the new ESOP plan suggests a need to monitor future management compensation and dilution.
Caplin Steriles gets USFDA approval for Acetaminophen Injection
Caplin Point Laboratories' subsidiary, Caplin Steriles Limited, received USFDA approval for Acetaminophen Injection, 1000 mg/100 mL (10 mg/mL) Single-dose Infusion Bags. This is a generic version of the Reference Listed Drug (RLD) from Mallinckrodt Pharmaceuticals Ireland Limited. Acetaminophen Injection had US sales of approximately $86 million for the 12-month period ending October 2025. Caplin Steriles has 43 ANDA approvals so far and is working on 40+ injectable and ophthalmic products.
Key Highlights
USFDA approval received for Acetaminophen Injection, 1000 mg/100 mL (10 mg/mL)
Acetaminophen Injection had US sales of approximately $86 million (ending October 2025)
Caplin Steriles has developed and filed 53 ANDAs in USA
Caplin Steriles has 43 ANDA approvals so far
💼 Action for Investors
This approval is a positive sign for Caplin Point Laboratories. Investors should monitor the sales and market share of Acetaminophen Injection in the coming quarters.
Sinclairs Hotels: Unaudited Financial Results for Quarter Ended Sept 30, 2025
Sinclairs Hotels Limited announced unaudited financial results for the quarter and half year ended September 30, 2025. The company reported a total income of ₹929.06 lakh for the quarter ended September 30, 2025, compared to ₹1,181.69 lakh for the quarter ended September 30, 2024. The profit/(loss) before tax for the quarter ended September 30, 2025, was a loss of ₹276.27 lakh, compared to a profit of ₹299.81 lakh for the quarter ended September 30, 2024. Basic and diluted earnings per share stood at ₹(0.40) for the quarter ended September 30, 2025.
Key Highlights
Revenue from operations for the quarter ended September 30, 2025, was ₹898.48 lakh.
Total expenses for the quarter ended September 30, 2025, amounted to ₹1,205.33 lakh.
Loss for the period for the quarter ended September 30, 2025, was ₹203.59 lakh.
Finance costs for the quarter ended September 30, 2025, were ₹80.86 lakh.
The 95-room Sinclairs Palace Retreat Udaipur commenced operations on August 1, 2025.
💼 Action for Investors
Investors should review the detailed financial results on the company's website and monitor the impact of the new Udaipur hotel on future performance. Consider the seasonal nature of the business when evaluating quarterly results.
Asian Hotels (West) Reports FY25 Results; Auditors Issue Adverse Opinion Over Going Concern
Asian Hotels (West) Limited has released its FY25 audited results, which were met with an adverse opinion from statutory auditors due to significant financial irregularities and going concern doubts. The company's current liabilities exceed current assets by ₹420.52 crore, and there is ambiguity regarding a ₹390 crore fund infusion from the Saraf Group, which may be an advance for the sale of Hyatt Regency Mumbai. Additionally, the company failed to recognize interest expenses of ₹38.51 crore and lacks proper records for fixed assets worth ₹16.17 crore. The board also approved management changes, including the appointment of Rohit Rajpal as an Independent Director.
Key Highlights
Statutory auditors issued an adverse opinion on FY25 results citing material uncertainties and going concern doubts.
Current liabilities exceed current assets by ₹420.52 crore as of March 31, 2025.
Company failed to recognize interest expenses totaling ₹38.51 crore and reimbursement expenses of ₹4.54 crore.
Ambiguity exists over ₹390 crore received from Saraf Group, which may be an advance for the sale of the Hyatt Regency Mumbai asset.
Auditors were unable to verify the existence of Property, Plant, and Equipment (PPE) valued at ₹16.17 crore.
💼 Action for Investors
Investors should exercise extreme caution as the adverse auditor opinion and significant liquidity mismatch indicate high financial and governance risks. The lack of clarity regarding the potential sale of the company's primary asset and missing fixed asset records are major red flags.
Emmvee Subsidiary Secures Massive 4.5 GWp Solar Cell Supply Agreement
Emmvee Photovoltaic Power Limited's wholly-owned subsidiary, Emmvee Energy Private Limited, has entered into a significant supply agreement with a domestic buyer. The contract entails the supply of 4.5 GWp of TOPCon crystalline silicon photovoltaic cells. The execution is scheduled over a five-year period from December 2025 to 2030. This deal provides substantial long-term revenue visibility and validates the company's technological capabilities in the high-efficiency solar segment.
Key Highlights
Contracted offtake of 4.5 GWp for TOPCon crystalline silicon photovoltaic cells
Agreement signed by material subsidiary Emmvee Energy Private Limited
Execution timeline set for a 5-year period from December 2025 to 2030
The deal involves a domestic buyer and is not a related party transaction
💼 Action for Investors
This is a major win providing long-term revenue visibility; investors should track the company's manufacturing progress and margin profile for TOPCon cells as execution begins in late 2025.
Sinclairs Hotels Reports Q2 Net Loss of ₹2.04 Cr; Revenue Up 11% YoY
Sinclairs Hotels reported a net loss of ₹2.04 crore for Q2 FY26, a sharp decline from a profit of ₹2.24 crore in the previous year's corresponding quarter. While operational revenue grew by 11.1% YoY to ₹8.98 crore, the bottom line was hit by a significant increase in expenses, which rose 36.7% to ₹12.05 crore. The surge in costs is primarily attributed to higher depreciation and finance charges following the commencement of the 95-room Udaipur property in August 2025. Management noted that Q2 is seasonally weak and the results reflect the initial impact of the new expansion.
Key Highlights
Revenue from operations increased 11.1% YoY to ₹898.48 lakh in Q2 FY26.
Reported a net loss of ₹203.59 lakh for the quarter compared to a profit of ₹224.24 lakh in Q2 FY25.
Total expenses jumped to ₹1,205.33 lakh from ₹881.88 lakh YoY, driven by expansion-related costs.
The 95-room 'Sinclairs Palace Retreat Udaipur' commenced operations on August 1, 2025.
H1 FY26 net profit stood at ₹414.89 lakh, down from ₹909.05 lakh in H1 FY25.
💼 Action for Investors
Investors should closely watch the occupancy and revenue ramp-up of the new Udaipur property to see if it can offset the increased fixed costs in the coming quarters. The current loss appears to be a transitionary phase due to expansion, but short-term stock performance may remain subdued.
Embassy Developments sells 450+ units worth ~₹860 Crore at Embassy Greenshore launch
Embassy Developments Limited (EMBDL) has announced the successful launch of Embassy Greenshore, a premium residential project within Embassy Springs in North Bengaluru. The company sold over 450 units, generating bookings worth approximately ₹860 crore within five days of the launch. Phase 1 comprised 700 units spread over 1.34 million sq. ft. The project spans ~14 acres with 1.55 million sq. ft. of saleable area and includes 878 apartments across two phases.
Key Highlights
Sold 450+ units at Embassy Greenshore launch.
Bookings worth ~₹860 Crore achieved within five days.
Phase 1 comprises 700 units spread over 1.34 million sq. ft.
Project spans ~14 acres with 1.55 million sq. ft. of saleable area.
878 apartments across two phases.
💼 Action for Investors
The strong sales figures are a positive sign for Embassy Developments. Investors should monitor the progress of the Embassy Greenshore project and the launch of Phase 2 in January 2026.
ICICI Pru Life Nov 2025: Retail APE Surges 25.1% YoY Despite 40.5% Drop in Total NBP
ICICI Prudential Life Insurance reported a mixed performance for November 2025, highlighted by a robust 25.1% YoY growth in Retail Annualized Premium Equivalent (APE) to ₹7.18 billion. However, total New Business Premium (NBP) for the month saw a sharp decline of 40.5% YoY, falling to ₹19.16 billion. On a cumulative 8-month basis (8M-FY2026), the company's APE and NBP are down by 2.6% and 3.2% respectively. Despite the premium volatility, the New Business Sum Assured grew by 13.8% YoY in November, indicating continued expansion in risk coverage.
Key Highlights
Retail APE grew significantly by 25.1% YoY to ₹7.18 billion in November 2025.
Total New Business Premium (NBP) declined by 40.5% YoY to ₹19.16 billion for the month.
Retail Weighted Received Premium (RWRP) increased 13.2% YoY to ₹6.50 billion in November.
Cumulative 8M-FY2026 APE stands at ₹58.82 billion, down 2.6% compared to the previous year.
New Business Sum Assured for November 2025 rose 13.8% YoY to ₹1,087.20 billion.
💼 Action for Investors
Investors should focus on the strong recovery in the retail segment (Retail APE) while monitoring the reasons behind the sharp 40% drop in total monthly NBP. The divergence between retail growth and total premium suggests a potential shift in product mix or institutional business volatility.
SAILIFE: Order passed under GST Act with demand of ₹8.8 Cr
Sai Life Sciences has received an order from the Joint Commissioner of Commercial Taxes (Appeals), Kalaburagi under the Karnataka Goods and Services Tax Act, 2017. The order demands IGST of ₹4,62,36,986, Cess of ₹291,659, Interest of ₹3,20,77,995, and a Penalty of ₹92,76,563, totaling approximately ₹8.8 crores. The demand relates to alleged excess availment of ITC and discrepancies in B2B supply records for FY 2020-21. The company plans to appeal the order and anticipates a favorable outcome, expecting no material financial impact.
Key Highlights
IGST demand of ₹4,62,36,986
Cess demand of ₹291,659
Interest demand of ₹3,20,77,995
Penalty of ₹92,76,563 imposed
Order passed under Section 107 (11) of the GST Act, 2017
💼 Action for Investors
Investors should monitor the progress of the appeal process. While the company expects a favorable outcome, any adverse ruling could potentially impact its financials.